Nelson Jeffrey Edward 4

What Happened
Nelson Jeffrey Edward (COO) received two derivative awards from Milestone Pharmaceuticals on February 2, 2026: a grant of 204,000 option-type shares and 136,000 restricted stock units (RSUs), for a total of 340,000 shares. Both awards were reported as acquired at $0.00 per share (standard for equity grants); these are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-02-02; Filing date: 2026-02-04 (timely).
• Awards: 204,000 (derivative option-style award) and 136,000 RSUs; combined 340,000 shares; acquisition price reported $0.00.
• Vesting for the 204,000-option award: 1/4 vest on Feb 2, 2027, then 1/36 of the remainder each month thereafter, subject to continued service (Footnote F1).
• RSU details: each RSU converts to one common share (Footnote F2). RSU vesting: 1/4 on each of Feb 2, 2027, 2028, 2029 and 2030 (Footnote F3).
• Shares owned after the transaction: not specified in the filing.
• Filing legend/codes: Transaction code A = Award/Grant; these are derivative grants, not immediate sales or purchases.

Context
These awards are typical executive compensation meant to retain and incentivize management — they vest over multiple years and do not represent immediate cash proceeds or an open-market purchase. For retail investors, note that such grants become economically meaningful only as they vest and, for options, if exercised; they do not necessarily indicate a near-term insider buy or sell.